Why the Mesoblast (ASX:MSB) share price is surging 14%

The Mesoblast (ASX: MSB) share price is surging today after the company reported promising COVID-19 trial results in its quarterly update.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Limited (ASX: MSB) share price is surging this morning after the Aussie company's latest quarterly results. The cellular medicine manufacturer provided an update for the third quarter ended 31 March 2021 (Q3 2021). 

At the time of writing, the Mesoblast share price is trading at $2.09, up 14.21%. 

Why is the Mesoblast share price rocketing?

The Aussie medicine company this morning announced results from its COVID-19 acute respiratory distress syndrome (ARDS) trial.

Mesoblast CEO Silviu Itescu said, "We are very excited about the top-line results announced today from the trial of remestemcel-L in patients on mechanical ventilation due to COVID-19".

Results showed that patients receiving remestemcel-L had reduced mortality through 60 days in the pre-specified population under 65 years old. In fact, those using Mesoblast's drug saw 46% lower mortality through day 50.

The trial also showed mortality reduction from the drug was "accompanied by increased days alive off mechanical ventilation and reduced days in hospital".

Mr Itescu said the results have "the potential to make a substantial impact in outcomes for this critical patient population". Investors are driving the Mesoblast share price higher in early trade on the back of this morning's trial updates.

Mesoblast has now entered into a license and collaboration agreement with Novartis for the development, manufacture and commercialisation of remestemcel-L with an initial focus on treating severe COVID-19.

The company also completed a US$110 million private placement during the quarter. That helped boost the company's cash balance to US$158.3 million at quarter-end with net cash usage of US$25.8 million. 

The Aussie healthcare group continues to engage with the United States Food and Drug Administration (FDA). Mesoblast is seeking to gain approval to use remestemcel-L in treating steroid-refractory Acute Graft Versus Host Disease.

In further news driving the Mesoblast share price, results from the company's chronic lower back pain (CLBP) trial were also promising. The results indicated that treatment "may be greatest when inflammation is high and before irreversible fibrosis has occurred in the intervertebral disc".

Foolish takeaway

The March quarter was another action-packed one for the biotech and has resulted in the Mesoblast share price surging higher this morning. This will come as welcome news for shareholders, with the company's shares still trading around 20% lower since mid-February. 

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »